| 2024-10 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study |
Oncologist. 2024 Oct 3;29(10):e1396-e1405. |
 |
| 2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri |
Gastric Cancer. 2024 Aug 20;Article in Press. |
|
| 2024-08-06 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer |
ESMO Open. 2024 Aug 06;9(8):Article number 103647. |
|
| 2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study |
Lancet. Gastroenterology and Hepatology. 2024 Aug;9(8):694-704. |
|
| 2024-07-11 |
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study |
BMC Cancer. 2024 Jul 11;24:Article number 828. |
|
| 2024-06-21 |
Topiramate suppresses peri-infarct spreading depolarization and improves outcomes in a rat model of photothrombotic stroke |
iScience. 2024 Jun 21;27(6):Article number 110033. |
|
| 2024-06-17 |
Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer |
Future Oncology. 2024 Jun 17;Article in Press. |
|
| 2024-05 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer |
Pancreatology. 2024 May;24(3):600-607. |
|
| 2024-03 |
RNF43 inactivation enhances the B-RAF/MEK signaling and greates a combinatory therapeutic target in cancer cells |
Advanced Science. 2024 Mar;11(12):Article number e2304820. |
|
| 2024-02-20 |
Chromatin remodeling-related PRDM1 increases stomach cancer proliferation and is counteracted by bromodomain inhibitor |
Journal of Personalized Medicine. 2024 Feb 20;14(3):Article number 224. |
|
| 2024-02-15 |
Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway |
American Journal of Cancer Research. 2024 Feb 15;14(2):448-466. |
|
| 2024-02-13 |
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan |
Journal of Biomedical Science. 2024 Feb 13;31:Article number 21. |
|
| 2024-02-01 |
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression |
Liver Cancer. 2024 Feb 01;Article in Press. |
|
| 2023-11-22 |
The prognosis performance of a neutrophil- and lymphocyte-associated gene mutation score in a head and neck cancer cohort |
Biomedicines. 2023 Nov 22;11(12):Article number 120209. |
|
| 2023-11 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer |
Future Oncology. 2023 Nov;19(34):2277-2289. |
|
| 2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome |
Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390. |
|
| 2023-11 |
Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis |
Annals of Oncology. 2023 Nov;34(Suppl. 4):S1536-S1537. |
|
| 2023-10 |
The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: A noninterventional, uncontrolled multicenter study |
British Journal of Cancer. 2023 Oct;129(6):947-955. |
|
| 2023-10 |
Risk of type 2 diabetes mellitus and hyperlipidemia in patients with chronic myeloid leukemia initiating tyrosine kinase inhibitors: A nationwide cohort study |
Pharmacoepidemiology and Drug Safety. 2023 Oct;32(Suppl. S1):575. |
|
| 2023-09-01 |
The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study |
International Journal of Surgery. 2023 Sep 1;109(9):2614-2623. |
|
| 2023-09 |
Carbohydrate antigen 19-9 response to initial adjuvant chemotherapy predicts survival and failure pattern of resected pancreatic adenocarcinoma but not which patients are suited for additional adjuvant chemoradiation therapy: From a prospective randomized study |
International Journal of Radiation Oncology Biology Physics. 2023 Sep 1;117(1):74-86. |
|
| 2023-08-15 |
Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination |
American Journal of Cancer Research. 2023 Aug 15;13(8):3417-3432. |
|
| 2023-08 |
The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study |
Cancer Medicine. 2023 Aug;12(16):16906-16917. |
|
| 2023-07 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462 |
Annals of Oncology. 2023 Jul;34(7):633. |
|
| 2023-06 |
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors |
Journal of Clinical Oncology. 2023 Jun;41(16, Suppl.):Meeting Abstract 3148. |
|
| 2023-05-24 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer |
ESMO Open. 2023 May 24;8(3):Article number 101558. |
|
| 2023-05-01 |
The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy |
Experimental and Molecular Medicine. 2023 May;55(5):926-938. |
|
| 2023-02-24 |
Deciphering the functions of telomerase reverse transcriptase in head and neck cancer |
Biomedicines. 2023 Feb 24;11(3):Article number 691. |
|
| 2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer |
Cancers. 2023 Feb 5;15(4):Article number 1008. |
|
| 2023-02 |
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan |
ESMO Open. 2023 Feb;8(1):Article number 100746. |
|
| 2023-01-21 |
Adjuvant therapy in biliary tract cancers: Oral fluoropyrimidine as a beginning |
Lancet. 2023 Jan 21-27;401(10372):170-171. |
|
| 2023-01-20 |
ARID1A loss in pancreas leads to islet developmental defect and metabolic disturbance |
iScience. 2023 Jan 20;26(1):Article number 105881. |
|
| 2023-01-19 |
Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma |
New England Journal of Medicine. 2023 Jan 19;388(3):228-239. |
|
| 2023-01-06 |
Visible CCD camera-guided photoacoustic imaging system for precise navigation during functional rat brain imaging |
Biosensors. 2023 Jan 6;13(1):Article number 107. |
|
| 2023-01 |
TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIdelta/AKT pathway |
Journal of Advanced Research. 2023 Jan;43:45-57. |
|
| 2022-12-28 |
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan |
Scientific Reports. 2022 Dec 28;12:Article number 22492. |
|
| 2022-12-15 |
Skp2-mediated Zeb1 expression facilitates cancer migration by a ubiquitination-independent pathway |
Life Sciences. 2022 Dec 15;311(Part A):Article number 121135. |
|
| 2022-11-06 |
PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation |
Journal of Biomedical Science. 2022 Nov 06;29:Article number 92. |
|
| 2022-11-01 |
Revisiting the cerebral hemodynamics of awake, freely moving rats with repeated ketamine self-administration using a miniature photoacoustic imaging system |
Neurophotonics. 2022 Nov 01;9(4):Article number 045003. |
|
| 2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) |
Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462-S1463. |
|
| 2022-10 |
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma |
Hepatology International. 2022 Oct;16(5):1137-1149. |
|
| 2022-10 |
Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study |
Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257. |
|
| 2022-10 |
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression |
Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412. |
|
| 2022-09-21 |
Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer |
International Journal of Medical Sciences. 2022 Sep 21;19(10):1615-1627. |
|
| 2022-09-15 |
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin |
American Journal of Cancer Research. 2022 Sep 15;12(9):4267-4278. |
|
| 2022-09 |
A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study |
European Journal of Cancer. 2022 Sep;173:123-132. |
|
| 2022-09 |
Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan |
Liver Cancer. 2022 Sep;11(5):426-439. |
|
| 2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) |
Annals of Oncology. 2022 Sep;33(7):S565-S566. |
|
| 2022-07 |
Toward collaboration among cancer trials groups in Asia: TCOG perspective |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S449. |
|
| 2022-07 |
Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S535. |
|
